Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Anemia in chronic kidney disease is common and iron deficiency is an important cause. To repair iron-deficiency anemia, replacement of iron is needed. Iron can be replaced either by the oral route or by the intravenous route. In a meta-analysis, 5 of the 6 trials were short-term, 1 to 3 months, and compared to oral iron, the mean increase in hemoglobin with intravenous iron was only 0.31 g/dL. However, one of the studies included in this meta-analysis was 6 months long and had a mean decline in hemoglobin of 0.52 g/dL associated with intravenous iron administration. Given the short duration of most of the clinical trials comparing oral with intravenous administration of iron the long-term safety of these modes of administration of supplemental iron could not be assessed. Replacement of iron by the oral route is associated with mostly minor complications such as black stools, constipation, and abdominal discomfort. In contrast, intravenous administration of iron may lead to severe adverse events such as anaphylaxis and, as a more recent randomized trial has suggested, delayed complications such as infections and cardiovascular disease. Delayed complications of repeated intravenous iron use are difficult to recognize at an individual level therefore inpatients who have had recent cardiovascular events or are infected, intravenous iron should probably be avoided. Balancing safety and efficacy would require clinical judgment because 1 size may not fit all till we have better data to support the liberal use of parenteral iron.

Original languageEnglish (US)
Pages (from-to)S78-S82
JournalHemodialysis International
Volume21
DOIs
StatePublished - Jul 1 2017

Fingerprint

Iron-Deficiency Anemias
Chronic Renal Insufficiency
Uncertainty
Iron
Intravenous Administration
Meta-Analysis
Hemoglobins
Safety
Anaphylaxis
Constipation
Anemia
Inpatients
Cardiovascular Diseases

Keywords

  • Chronic kidney disease
  • efficacy
  • iron deficiency anemia
  • randomized trials
  • safety issues

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Iron deficiency anemia in chronic kidney disease : Uncertainties and cautions. / Agarwal, Rajiv.

In: Hemodialysis International, Vol. 21, 01.07.2017, p. S78-S82.

Research output: Contribution to journalReview article

@article{f8bcf38cca4743fd916ab06bb2ca1a9b,
title = "Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions",
abstract = "Anemia in chronic kidney disease is common and iron deficiency is an important cause. To repair iron-deficiency anemia, replacement of iron is needed. Iron can be replaced either by the oral route or by the intravenous route. In a meta-analysis, 5 of the 6 trials were short-term, 1 to 3 months, and compared to oral iron, the mean increase in hemoglobin with intravenous iron was only 0.31 g/dL. However, one of the studies included in this meta-analysis was 6 months long and had a mean decline in hemoglobin of 0.52 g/dL associated with intravenous iron administration. Given the short duration of most of the clinical trials comparing oral with intravenous administration of iron the long-term safety of these modes of administration of supplemental iron could not be assessed. Replacement of iron by the oral route is associated with mostly minor complications such as black stools, constipation, and abdominal discomfort. In contrast, intravenous administration of iron may lead to severe adverse events such as anaphylaxis and, as a more recent randomized trial has suggested, delayed complications such as infections and cardiovascular disease. Delayed complications of repeated intravenous iron use are difficult to recognize at an individual level therefore inpatients who have had recent cardiovascular events or are infected, intravenous iron should probably be avoided. Balancing safety and efficacy would require clinical judgment because 1 size may not fit all till we have better data to support the liberal use of parenteral iron.",
keywords = "Chronic kidney disease, efficacy, iron deficiency anemia, randomized trials, safety issues",
author = "Rajiv Agarwal",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/hdi.12561",
language = "English (US)",
volume = "21",
pages = "S78--S82",
journal = "Hemodialysis International",
issn = "1492-7535",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Iron deficiency anemia in chronic kidney disease

T2 - Uncertainties and cautions

AU - Agarwal, Rajiv

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Anemia in chronic kidney disease is common and iron deficiency is an important cause. To repair iron-deficiency anemia, replacement of iron is needed. Iron can be replaced either by the oral route or by the intravenous route. In a meta-analysis, 5 of the 6 trials were short-term, 1 to 3 months, and compared to oral iron, the mean increase in hemoglobin with intravenous iron was only 0.31 g/dL. However, one of the studies included in this meta-analysis was 6 months long and had a mean decline in hemoglobin of 0.52 g/dL associated with intravenous iron administration. Given the short duration of most of the clinical trials comparing oral with intravenous administration of iron the long-term safety of these modes of administration of supplemental iron could not be assessed. Replacement of iron by the oral route is associated with mostly minor complications such as black stools, constipation, and abdominal discomfort. In contrast, intravenous administration of iron may lead to severe adverse events such as anaphylaxis and, as a more recent randomized trial has suggested, delayed complications such as infections and cardiovascular disease. Delayed complications of repeated intravenous iron use are difficult to recognize at an individual level therefore inpatients who have had recent cardiovascular events or are infected, intravenous iron should probably be avoided. Balancing safety and efficacy would require clinical judgment because 1 size may not fit all till we have better data to support the liberal use of parenteral iron.

AB - Anemia in chronic kidney disease is common and iron deficiency is an important cause. To repair iron-deficiency anemia, replacement of iron is needed. Iron can be replaced either by the oral route or by the intravenous route. In a meta-analysis, 5 of the 6 trials were short-term, 1 to 3 months, and compared to oral iron, the mean increase in hemoglobin with intravenous iron was only 0.31 g/dL. However, one of the studies included in this meta-analysis was 6 months long and had a mean decline in hemoglobin of 0.52 g/dL associated with intravenous iron administration. Given the short duration of most of the clinical trials comparing oral with intravenous administration of iron the long-term safety of these modes of administration of supplemental iron could not be assessed. Replacement of iron by the oral route is associated with mostly minor complications such as black stools, constipation, and abdominal discomfort. In contrast, intravenous administration of iron may lead to severe adverse events such as anaphylaxis and, as a more recent randomized trial has suggested, delayed complications such as infections and cardiovascular disease. Delayed complications of repeated intravenous iron use are difficult to recognize at an individual level therefore inpatients who have had recent cardiovascular events or are infected, intravenous iron should probably be avoided. Balancing safety and efficacy would require clinical judgment because 1 size may not fit all till we have better data to support the liberal use of parenteral iron.

KW - Chronic kidney disease

KW - efficacy

KW - iron deficiency anemia

KW - randomized trials

KW - safety issues

UR - http://www.scopus.com/inward/record.url?scp=85017548246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017548246&partnerID=8YFLogxK

U2 - 10.1111/hdi.12561

DO - 10.1111/hdi.12561

M3 - Review article

C2 - 28403561

AN - SCOPUS:85017548246

VL - 21

SP - S78-S82

JO - Hemodialysis International

JF - Hemodialysis International

SN - 1492-7535

ER -